Vitamin D and incident urinary incontinence in older adults

Elizabeth Vaughan, Emory University
Vin Tangpricha, Emory University
Nary Motahar, Emory University
Patricia S Goode, Birmingham/Atlanta Geriatric Research
Kathryn L Burgio, Birmingham/Atlanta Geriatric Research
Richard M Allman, Department of Veterans Affairs
Shanette G Daigle, Birmingham/Atlanta Geriatric Research
David T Redden, Birmingham/Atlanta Geriatric Research
Alayne D Markland, Birmingham/Atlanta Geriatric Research

Journal Title: European Journal of Clinical Nutrition
Volume: Volume 70, Number 9
Publisher: Nature Publishing Group: Open Access Hybrid Model Option B | 2016-09-01, Pages 987-989
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1038/ejcn.2016.20
Permanent URL: https://pid.emory.edu/ark:/25593/rrnk

Final published version: http://dx.doi.org/10.1038/ejcn.2016.20

Copyright information:
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

Accessed September 30, 2020 6:07 AM EDT
Vitamin D and Incident Urinary Incontinence in Older Adults

Camille P Vaughan, MD, MS, Vin Tangpricha, MD, PhD, N Motahar-Ford, MD, Patricia S Goode, MD, MSN, Kathryn L Burgio, PhD, Richard M Allman, MD, Shanette G Daigle, MPH, David T Redden, PhD, and Alayne D Markland, DO, MSc

aBirmingham/Atlanta Geriatric Research, Education, and Clinical Center, Department of Veterans Affairs, Birmingham, Alabama and Atlanta, Georgia
bAtlanta Veterans Affairs Medical Center, Decatur, Georgia
bDepartment of Medicine, Emory University, Atlanta, Georgia
dDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL
eComprehensive Center for Healthy Aging, University of Alabama at Birmingham, Birmingham, AL
fDepartment of Veterans Affairs, Office of Geriatrics and Extended Care, Washington, D.C
gSchool of Public Health, University of Alabama at Birmingham, Birmingham, AL

Abstract

Objective—To determine if vitamin D status is associated with incident urinary incontinence (UI) among community-dwelling older adults.

Methods—The University of Alabama at Birmingham Study of Aging is a prospective cohort study of community-dwelling Medicare enrollees. Standardized assessment of UI using the validated Incontinence Severity Index. Analysis of 25-hydroxyvitamin D (25(OH)D) levels was performed on stored baseline sera. UI was assessed every 6–12 months for up to 42 months. Analyses included multivariable logistic regression and Cox proportional hazard models.

Results—Of 350 participants (175 male, 147 black, mean age 73.6 ± 5.8), 54% (189/350) were vitamin D deficient [25(OH)D < 20 ng/mL] and 25% (87/350) were vitamin D insufficient
[25(OH)D 20 ng/mL to < 30 ng/mL]. Among the 187 subjects with no UI at baseline, 57% (107/187) were vitamin D deficient and 24% (45/187) were vitamin D insufficient. 175 of the 187 subjects had follow-up evaluation for incident UI over 42 months and incident UI occurred in 37% (65/175). After adjustment cumulative incident UI at 42 months was associated with baseline vitamin D insufficiency (p=0.03) and demonstrated a trend association with deficiency (p=0.07). There was no association between baseline vitamin D status and time to incident UI.

Conclusions—These preliminary results support an association between vitamin D and incident UI in community-dwelling older adults. Future studies may target specific at risk groups, such as men with BPH or women with pelvic floor disorders for evaluation of the impact of vitamin D supplementation on urinary symptoms.

INTRODUCTION

The prevalence of urinary incontinence (UI) is increased among older adults and is associated with poor quality of life, social isolation, falls, and depression(1–4). Treatment is usually multifactorial involving lifestyle, behavioral and often pharmacologic therapies(5). Drug therapy for UI is associated with the potential for adverse events and, may have significant cost; thus adherence is often maintained for only a few months(6, 7). Additional treatment modalities are needed in order to maximize the impact of multicomponent therapy and reduce the potential for adverse events.

Recent studies have suggested a relationship between vitamin D and conditions increasing the risk of UI among both men and women. Vitamin D receptors are present in the bladder and striated muscle of the pelvic floor musculature(8, 9). Additionally, prostatic cells express 1α-hydroxylase and can synthesize 1,25-di-hydroxyvitamin D (the active form of vitamin D)(10). Low vitamin D levels are associated with increased prevalence of pelvic floor disorders among women and moderate-to-severe UI in men(11–13). However, these studies are based on cross-sectional data. One randomized controlled trial demonstrated treatment with a vitamin D analog reduced prostate enlargement in the setting of benign prostatic hyperplasia(14).

Evaluation of data assessing the longitudinal relationship between vitamin D and incident UI would allow for additional insights and provide next steps in determining the need for interventional studies. Thus, our aim was to evaluate the association of low vitamin D with incident UI in a cohort of community-dwelling older adults.

METHODS

Subjects

The University of Alabama at Birmingham Study of Aging (SOA) is a longitudinal cohort study of community-dwelling older adults designed to assess factors associated with changes in mobility. Between 1999 and 2001 the study recruited 1,000 individuals 65 years of age and older from five counties in west central Alabama, including 3 rural counties and 2 urban counties. Individuals were randomly selected from Medicare beneficiary lists stratified by race and gender so that the cohort included equal numbers of men and women, black and white, and urban and rural residence. Exclusion criteria included: inability to understand the
recruiter, residing in nursing homes, or inability to independently coordinate an appointment for the baseline, in-home interview. The institutional review board at the University of Alabama at Birmingham approved the study and written informed consent was obtained prior to beginning study procedures.

At baseline and in 2004, a two-hour, in-home assessment was performed, which included a medical history, cognitive screening test, screening for depression, assessment of activities of daily living, and questions regarding multiple facets of functional status. Eligibility for the in-home follow-up in 2004 was the same as the baseline evaluation with 624 of 733 (85.1%) of surviving participants agreeing to the in-home assessment in 2004(15). These 624 participants were offered the opportunity to have a blood test obtained, and 408 (65.4%) agreed to the lab test. Blood samples were used to measure multiple laboratory assays, but not vitamin D levels. Serum samples were stored in −70 degree freezers for future use. Vitamin D analyses were completed in 2013 for 350 of the 408 (85.8%) participants who had a blood sample obtained and had sufficient serum available for the vitamin D assays.

Of these participants with vitamin D data available, 187/350 (53.4%) did not have UI in 2004. Follow-up incident UI data were available on 175/187 (94.6%) of these participants. Thus, prevalence of vitamin D deficiency and insufficiency was assessed using 350 participants; while the 175 participants without UI in 2004 and with follow-up incident UI data were the focus of the current analysis. Every six to twelve months, participants were contacted by phone to complete a questionnaire including information about UI.

**Urinary Incontinence Assessment**

Participants provided information about the presence of UI using the validated two-item Incontinence Severity Index, which correlates well with UI measured with 24-hour pad weights and UI frequency on bladder diaries(16). Participants were asked, "Have you ever leaked even a small amount of urine?" and "How often does that occur?" Incident UI was classified as an affirmative response to the first question and a response to the second question of at least monthly UI.

**Vitamin D Assessment**

Analysis of serum concentrations of 25-hydroxyvitamin D [25(OH)D] was performed on stored sera using an IDS-iSYS analyzer. To ensure quality control of the vitamin D assay, the laboratory participates in the vitamin D external quality assessment scheme every 3 months and in the NIST/NIH Vitamin D Metabolites Quality Assurance Program semi-annually. For the purposes of this evaluation, vitamin D deficiency was defined as a serum 25-hydroxyvitamin D level < 20 ng/mL and vitamin D insufficiency as a 25-hydroxyvitamin D level from 20 ng/mL to < 30 ng/mL.

**Statistical Analysis**

Descriptive statistics were used to analyze baseline characteristics of the subsample (n=350) of UAB Study of Aging participants for which sera were available for vitamin D assays in 2004 and the 175 participants who were included in the incident UI analysis. Multivariable logistic regression and Cox proportional hazard models adjusted for age, gender, and race/
ethnicity were utilized to evaluate the relationship between vitamin D status and incident UI among those participants reporting no UI at baseline. All analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC).

RESULTS

Of the 350 participants who had serum samples available for vitamin D assays in 2004 (the baseline year for this analysis) (Table 1), 54% were vitamin D deficient [25(OH)D < 20 ng/mL] and 25% were vitamin D insufficient [25(OH)D 20 ng/mL to < 30 ng/mL] (Table 1). Among the 187 subjects with no UI at baseline, 57% (107/187) were vitamin D deficient and 24% (45/187) were vitamin D insufficient. For these 187 subjects, the mean baseline 25(OH)D level was 20.5 ng/mL ± 9.7.

Mean length of follow-up was 34.5 months (range 6 – 42). For the 175 of the 187 subjects who had follow-up evaluation for incident UI over 42 months, incident UI occurred in 37% (65/175, 37% of women and 38% of men). These 175 participants generally reflected the demographic distribution of the original SOA cohort and those included in a previous analysis of incident UI(17). Among those with vitamin D deficiency, 37/97 (38%) developed UI and among those with vitamin D insufficiency, 20/44 (45%) developed UI. This compared to 8/34 (23%) of those with sufficient levels of vitamin D. However, there was no statistically significant difference in the proportion of individuals developing incident UI during the study period by vitamin D status (p=0.13).

After adjustment for age, gender and race/ethnicity, cumulative incident UI at 42 months was associated with vitamin D insufficiency status at baseline [aOR 3.18 (95%CI 1.14–8.87), p = 0.03]. There was a trend toward association between baseline vitamin D deficiency and incident UI [2.47 (95%CI 0.93–6.53), p=0.07]. However, there was no association between vitamin D insufficiency or deficiency and time to incident UI in unadjusted (Log-rank p=0.19) or adjusted analyses (Cox model overall test of significance, p=0.14).

DISCUSSION

These results suggest a potential association between vitamin D and the development of UI among a racially diverse cohort of older men and women. An evaluation of the longitudinal association between vitamin D status and incident UI among older adults is novel. Previous cross-sectional data have suggested an association between low vitamin D status and lower urinary tract symptoms in men and women; however, these studies are limited because they cannot evaluate for causality(11, 12). The University of Alabama at Birmingham SOA is unique among longitudinal studies of aging populations because the study population is racially diverse, validated questionnaires were used to assess urinary symptoms, and stored serum samples were available.

There are several mechanisms by which vitamin D could exert influence on lower urinary tract function. Vitamin D receptors are present in the bladder and striated muscle of the pelvic floor musculature(8, 9). Skeletal muscle control and strength are vital for the voluntary control of the urethral sphincter and pelvic floor muscles and likely a significant
factor in achieving continence. A vitamin D analog was evaluated as a potential adjuvant treatment with tolterodine and demonstrated improved bladder capacity in an animal model of bladder outlet obstruction(18). Additionally, prostatic cells express 1α-hydroxylase and can synthesize 1,25 di-hydroxyvitamin D (the active form of vitamin D)(10). A recent study found a specific polymorphism of the vitamin D receptor uniquely linked to a protective effect for the development of lower urinary tract symptoms in men(19).

Current treatment guidelines for UI care recommend lifestyle changes and behavioral therapy as a first step followed by bladder relaxant drug therapy(5). Older adults are more susceptible to the anticholinergic adverse events from bladder drug therapy (constipation, reflux, cognitive changes, xerostomia), which occur frequently with the most commonly prescribed bladder relaxants. Additionally, these drugs can be costly and many patients discontinue drug therapy after a few months(6, 7). Vitamin D is a low cost, well-tolerated supplement and could provide an adjuvant treatment to currently recommended exercise-based behavioral therapy.

Vitamin D deficiency is highly prevalent. The results from the Study of Aging showing more than half of participants were deficient in vitamin D and more than 80% were insufficient or deficient are consistent with population-based estimates(20). Vitamin D has been implicated in multiple health conditions and the Institute of Medicine has called for additional studies to provide information about the role of vitamin D(21). Longitudinal studies evaluating vitamin D replacement rarely include outcomes related to bladder health(22, 23). The current results add to the growing body of literature focused on the potential for vitamin D status to impact the health of older adults.

There are limitations to this study. The assessment of the association of vitamin D deficiency with UI may have been limited by the small number of persons with a baseline serum 25-hydroxyvitamin D level of 30 ng/mL or greater (n=34). The Cox proportional hazard analyses are limited because UI was reported every 6–12 months, which could lead to left censoring. We were not able to ascertain if participants received interval non-pharmacologic treatments for their bladder symptoms during the 6–12 month assessments. The UAB Study of Aging was designed to assess factors impacting social mobility among community-dwelling older adults and did not query a comprehensive set of factors that might impact the development of incontinence in this population. Lastly, vitamin D could be a marker of better health and physical activity, which was not controlled for in this analysis.

**CONCLUSION**

Urinary incontinence is a burdensome condition with significant impact on quality of life for many adults as they age. Treatment strategies for geriatric conditions such as UI are often multicomponent; however, current drug therapy is limited because of the potential for adverse events and cost. These results add to a growing body of literature suggesting physiologic mechanisms, cross-sectional association studies, and now preliminary longitudinal research demonstrating a potential association between vitamin D and optimal pelvic floor function. Vitamin D offers a low cost, well-tolerated option that warrants further
evaluation in an interventional trial, particularly focused on a population of older adults with vitamin D insufficiency.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

**Funding:** This study was funded by the following: A Consortium Multi-Institutional Collaborative Translational Research Pilot award under grant numbers UL1TR000454 and UL1TR000165 from the National Center for Advancing Translational Sciences of the National Institutes of Health and Veterans Health Administration Career Development Awards (CDA-2) to Drs. Markland (B6126W) and Vaughan (1 IK2 RX000747-01). The University of Alabama at Birmingham Study of Aging was funded through NIA AG15062.

**References**

1. Fultz NH, Herzog AR. Self-reported social and emotional impact of urinary incontinence. J Am Geriatr Soc. 2001; 49(7):892–9. [PubMed: 11527480]
2. Brown JS, Wittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000; 48(7):721–5. [PubMed: 10894308]
3. Grimby A, Milsom I, Molander U, Wiklund I, Ekelund P. The influence of urinary incontinence on the quality of life of elderly women. Age Ageing. 1993; 22(2):82–9. [PubMed: 8470564]
4. Chiarelli PE, Mackenzie LA, Osmotherly PG. Urinary incontinence is associated with an increase in falls: a systematic review. Aust J Physiother. 2009; 55(2):89–95. [PubMed: 19463079]
5. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. J Urol. 2012; 188(6, Supplement):2455–63. [PubMed: 23098785]
6. Gopal M, Haynes K, Bellamy SL, Arya L.A. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008; 112(6):1311–8.
7. Verhamme KMC, Dieleman JP, Bleumink GS, Bosch JLHR, Stricker BHC, Sturkenboom MCJM. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol. 2003; 44(5):539–45. [PubMed: 14572751]
8. Crescioli C, Morelli A, Adorini L, Ferruzzi P, Luconi M, Vannelli GB, et al. Human Bladder as a Novel Target for Vitamin D Receptor Ligands. J Clin Endocrinol Metab. 2005; 90(2):962–72. [PubMed: 15572423]
9. Bischoff HA, Borchers M, Guad F, Duermueller U, Theiler R, Stahelin HB, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J. 2001; 33(1):19–24. [PubMed: 11352397]
10. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dial. 2005; 18(4):276–89. [PubMed: 16076349]
11. Badalian SS, Rosenbaum PF. Vitamin D and Pelvic Floor Disorders in Women: Results From the National Health and Nutrition Examination Survey. Obstet Gynecol. 2010; 115(4):795–803.
12. Vaughan CP, Johnson TM II, Goode PS, Redden DT, Burgio KL, Markland AD. Vitamin D and lower urinary tract symptoms among US men: results from the 2005–2006 National Health and Nutrition Examination Survey. Urology. 2011; 78(6):1292–7. [PubMed: 22014969]
13. Navaneethan PR, Kekre A, Jacob KS, Varghese L. Vitamin D deficiency in postmenopausal women with pelvic floor disorders. J Mid-life Health. 2015; 6(2):66–9.
14. Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, et al. BXL628, A Novel Vitamin D3 Analog Arrests Prostate Growth in Patients with Benign Prostatic Hyperplasia: A Randomized Clinical Trial. Eur Urol. 2006; 49(1):82–6. [PubMed: 16310924]
15. Allman RM, Sawyer P, Crowther M, Strothers HS, Turner T, Fouad MN. Predictors of 4-Year Retention Among African American and White Community-Dwelling Participants in the UAB Study of Aging. The Gerontologist. 2011; 51(suppl 1):S46–S58. [PubMed: 21565818]

16. Sandvik H, Seim A, Vanvik A, Hunskaar S. A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests. Neurourol Urodyn. 2000; 19(2):137–45. [PubMed: 10679830]

17. Goode PS, Burgio KL, Redden DT, Markland A, Richter HE, Sawyer P, et al. Population Based Study of Incidence and Predictors of Urinary Incontinence in Black and White Older Adults. J Urol. 2008; 179(4):1449–54. [PubMed: 18295279]

18. Streng T, Andersson K-E, Hedlund P, Gratzke C, Baroni E, D’Ambrosio D, et al. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. BJU Int. 2012; 110(2b):E125–E31. [PubMed: 22288904]

19. Cartwright R, Mangera A, Tikkinen KAO, Rajan P, Pesonen J, Kirby AC, et al. Systematic Review and Meta-analysis of Candidate Gene Association Studies of Lower Urinary Tract Symptoms in Men. Eur Urol. 2014; 66(4):752–68. [PubMed: 24491308]

20. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357(3):266–81. [PubMed: 17634462]

21. Ross, AC.; Taylor, CL.; Yaktine, AL.; Del Valle, HB., editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington, D.C: National Academies Press; 2010.

22. Hansen KE, Johnson R, Chambers KR, et al. Treatment of vitamin D insufficiency in postmenopausal women: A randomized clinical trial. JAMA Int Med. 2015

23. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, et al. Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D3 and/or Calcium (RECORD Trial). J Clin Endocrinol Metab. 2012; 97(2):614–22. [PubMed: 22112804]
Figure 1. Incident UI among Vitamin D Sufficient, Insufficient, and Deficient Participants (n=175)

Key:
- Sufficient Vitamin D (≥ 30 ng/mL)
- Insufficient Vitamin D (20 to < 30 ng/mL)
- Deficient Vitamin D (< 20 ng/mL)

Log-Rank p-value = 0.19
### Table 1
Baseline Characteristics of UAB Study of Aging Participants with Serum Samples (n=350) and Subgroup with Incident UI Evaluation (n=175)

| Characteristic          | Serum Sample available (n=350) | Incident UI Evaluation (n=175) | P value<sup>b</sup> |
|-------------------------|--------------------------------|-------------------------------|---------------------|
| Age (mean ± SD)         | 73.6 ± 5.8                     | 74.8 ± 6.0                    | 0.03                |
| Gender                  |                                |                               |                     |
| Female                  | 175 (50)                       | 98 (56)                       | 0.03                |
| Male                    | 175 (50)                       | 77 (44)                       |                     |
| Ethnicity               |                                |                               | <0.001              |
| Black                   | 147 (42)                       | 91 (48)                       |                     |
| White                   | 203 (58)                       | 84 (52)                       |                     |
| Vitamin D status        |                                |                               | 0.91                |
| Deficient (< 20 ng/mL)  | 189 (54)                       | 97 (55)                       |                     |
| Insufficient (20 – < 30 ng/mL) | 87 (25)             | 44 (25)                       |                     |

<sup>a</sup> Number (%) unless noted

<sup>b</sup> Chi-square or t-test